Drug Profile
Research programme: p38 kinase inhibitor - Pfizer
Alternative Names: SC-409; SD 0006Latest Information Update: 04 Aug 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Rheumatoid arthritis
Most Recent Events
- 04 Aug 2009 No development reported - Preclinical for Asthma in USA (PO)
- 04 Aug 2009 No development reported - Preclinical for Chronic obstructive pulmonary disease in USA (PO)
- 04 Aug 2009 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)